How Can a Pharma QA Team Use AI Every Day? 5 Practical Examples
AI's first QA wins are ordinary: find the SOP, pre-check the record, spot repeat deviations. Five everyday uses every decision stays human. Read on.
Quick answer: A pharma QA team’s first practical uses of AI are ordinary: retrieving the current standard operating procedure, prechecking a batch record before review, spotting repeat deviation themes, summarizing investigations, and building audit-question banks. AI assists with search and assembly; every review, decision, and signature stays human.
Most QA Heads picture “AI in pharma” as a release-decision robot and file it under someday. After ten years in pharmaceutical quality assurance, I’d file it under Tuesday. FDA issued 303 drug and biologics warning letters in fiscal year 2025, up 59% from 190 the year before. None of it gets fixed by a moonshot. The pressure lands on ordinary work finding, checking, reading where AI earns its keep first.
This post answers the everyday version of “how can QA use AI in pharma”: five examples, split the same way what AI does, and what your team still decides. I call that line the Does/Decides Split.
What does "everyday AI" actually mean for a QA team?
Assistance inside work your quality assurance team already does no new decision rights, no change to who signs:
- Finding the right standard operating procedure (SOP) in seconds
- Pre-checking a batch record for blanks before human review
- Spotting repeat deviation themes across the queue
- Summarizing long investigation files into working briefs
- Preparing audit-question banks before an inspection
In a late-2025 survey of 300 quality and manufacturing leaders, 94% of pharma respondents named poor employee adoption of the existing quality system a significant pain point (MasterControl/Method Research, 2026) the hard part is rarely the model. Help that lives inside existing work clears that bar. For the wider map: AI in pharma documentation for small and midsize QA teams.
Example 1 How can AI find the right SOP in seconds?
Ask a plain question “which SOP covers line clearance for compression, and which revision is current?” and a retrieval assistant answers with the passage, document number, and revision instead of a folder path. That is retrieval-augmented generation at its plainest, aimed at office work’s least glamorous number: McKinsey Global Institute’s 2012 estimate that employees spend 1.8 hours a day searching for information, before AI assistants existed. Anyone who has hunted a revision on a shared drive knows the pharma version. What AI does: searches the controlled document set and quotes its source. What the human still does: confirms the effective version in the document-control system before acting. Retrieval points at documents; it does not issue them.
AI’s first job in a QA department isn’t judgment. It’s fetch.
Example 2 How can AI pre-check a batch record for blanks before review?
Before a completed batch manufacturing record (BMR) reaches a reviewer, AI can flag what a tired eye misses at 4 p.m.blank fields, missing initials and dates, an uncrossed correction, an entry that disagrees with the master formula record. The reviewer opens with a flag list instead of a blind read. What AI cannot do is review. Under 21 CFR 211.192◆, production and control records are reviewed and approved by the quality unit; the pre-check just means attention lands on judgment instead of hunting blanks. The full lifecycle is the batch documentation deep-dive; what the reviewing signature creates is how QA release review turns an AI draft into a signed record.
A blank field found before review costs a correction. The same blank found by an inspector costs a finding.
Example 3 How can AI spot repeat deviation themes?
Individually, deviations get investigated. Collectively, they get forgotten. AI can read a year of deviation titles and surface what familiarity hides: the same room, the same step, the same shift, the same phrase “operator error” recurring across products. The reading now carries regulatory weight: FDA’s March 2026 draft guidance on Form 483 responses
(Docket FDA-2025-D-1504) expects investigations to extend to other batches and products where warranted a themes question first. What AI does: clusters, counts, and nominates candidates for trending. What the human still does: decides whether a theme is real, owns the root cause, and writes the corrective and preventive action (CAPA). A model can point at three deviations that rhyme. Only your team can say why.
Example 4 How can AI summarize a long investigation file?
A forty-page out-of-specification (OOS) investigation compresses to a one-page brief: what happened, what was tested, what was concluded, what was committed. Useful before management review, a client call, or the annual product quality review (APQR) anywhere someone needs a file’s shape fast. Two rules keep it safe. The summary is a working aid, never the record: the investigation file remains the ALCOA+ original, and nothing signed references only the digest. And anyone approving, closing, or defending the file reads the source. Which version regulators actually check is a discipline of its own. Summaries buy reading time, not the right to skip reading.
Example 5 How can AI help build an audit-question bank?
Give AI your last three internal audit reports and dosage forms; ask for the fifty questions an inspector would open with. Then rehearse, out loud. The climate rewards it: failure to follow quality-unit procedures under 21 CFR 211.22(d) was the most cited Form 483 observation for the fifth consecutive year 184 citations in FY2024 (FDA data). A bank built from your own findings turns audit prep from re-reading binders into rehearsing answers. What AI does: drafts the questions, groups them by system, maps each to the document an inspector would pull. What the human still does: everything an inspector actually grades the answers, the evidence, the walkthrough. Nobody ever passed an inspection on the strength of a question list.
What does AI never do in these five examples?
It never reviews, approves, signs, or decides regulation, not caution: 21 CFR 211.22 places approval authority with the quality unit; 211.192 assigns record review before release. Enforcement arrived April 2, 2026: FDA Warning Letter 320-26- 58 cited Purolea Cosmetics Lab under 21 CFR 211.22(c) for AI-generated documents used without quality-unit review the first AI-specific citation in a drug good manufacturing practice (GMP) warning letter. The firm has since ceased drug production (ECA Academy, 2026). The Does/Decides Split keeps all five on the right side of that letter:
| Everyday use | What AI does | What your team still decides |
|---|---|---|
| SOP retrieval | Finds and quotes the passage; names document and revision | Confirms the effective version; acts on it |
| Record pre-check | Flags blanks, missing initials, master mismatches | Performs the 211.192 review; signs |
| Deviation themes | Clusters and counts recurring patterns | Confirms the trend; owns root cause and CAPA |
| Investigation summaries | Compresses the file to a working brief | Reads the source before approving or defending |
| Audit preparation | Drafts question banks from findings | Gives the answers; produces the evidence |
“In ten years of QA, no inspector ever asked whether we used clever software. Every one asked who reviewed the record and who signed it. Everyday uses change how fast the paper moves never who answers for it.”
– Kinjal Patel, Senior Consultant QMS, Validation & GMP Compliance
When don't these five examples help?
Three conditions break them. A stale corpus. Retrieval over a drive full of superseded SOPs returns the wrong revision fast and confidently worse than a slow search. If your documents live as scans and stray copies, fix the groundwork first. Output treated as the record. The moment a summary or an AI-drafted page enters use without quality-unit review, you have recreated the Purolea failure; drafts must be unmistakably drafts, watermarked and uncontrolled when printed. The pre-check becomes the review. Attention decays when a machine “already checked.” A flag list narrows where a reviewer looks; the 211.192 obligation doesn’t shrink by a single field.
Where should your team start this week?
Pick one and run it as a shadow exercise on last month’s closed work. Retrieval and summarization are the safest openers both read-only. Compare an assistant’s pre-check of an already-signed batch record, or its summary of a closed investigation, against what your team found. One afternoon shows whether the assist is real and nothing in your quality
system changes while you learn. The decision on your desk is which ordinary job to hand AI first while every signature stays where 21 CFR 211.192 puts it. The wider map: the AI-in-pharma pillar.
FAQ
Frequently asked questions
At everyday depth, five things: retrieve the current standard operating procedure, source cited; pre-check completed batch records for blanks and mismatches, cluster deviations into themes worth trending, summarize long investigation files, and draft audit-question banks from your own findings history. All five are assistance with search and assembly. None reviews, approves, or signs those remain quality-unit acts under 21 CFR 211.22 and 211.192.
It compresses the unglamorous middle of QA work: finding, checking, reading, and preparing. A reviewer opens a batch record with a flag list instead of a blind read; an investigator sees which deviations rhyme across the year; audit preparation starts from a rehearsal list instead of binders. The decisions trend or noise, adequate or not, release or hold stay where they were, with the people accountable for them.
No, and the reason is regulatory before it is sentimental. 21 CFR 211.22 places approval and rejection authority with the quality unit, and 211.192 assigns production-record review to it before release; EU GMP Chapter 4 carries the same logic for records and signatures. A tool cannot hold that accountability. What changes is the mix of the job: less hunting and transcribing, more judgment per hour worked.
It can pre-check one: flag blanks, missing initials and dates, and entries that disagree with the master formula record. It cannot review or approve one, because a record exists as a record only after a qualified human reviews and signs it. FDA’s April 2026 warning letter to Purolea Cosmetics Lab cited 21 CFR 211.22(c) for exactly this line being crossed AI generated documents used without quality-unit review.
Yes. Regulators object to ungoverned AI, not to AI. Assistive uses that leave review, approval, and signatures with humans sit comfortably inside 21 CFR Part 11, EU GMP Annex 11, and ALCOA+ expectations, and EU regulators are drafting Annex 22 specifically to describe how artificial intelligence fits GMP systems. What each major regulator has actually said, agency by agency, has its own post in this series
Not to learn whether they help. The honest prerequisites are about your documents, not your tooling: a controlled, current document set for retrieval to search, deviations captured with enough text to cluster, and investigation files that exist digitally. Whatever you eventually deploy must sit under your document-control and computerized-system governance but the shadow-exercise stage is about proving value inside work you already do.
Retrieval or summarization. Both are read-only: they change how fast you find and digest documents, and nothing else about your quality system. Batch-record pre-checks and deviation trending come next, because they touch live workflows and deserve a shadow run against already-reviewed records first. Audit-question banks are a strong third low risk, andimmediately felt the week before an inspection.
Letting an output quietly become a record. A summary filed as the investigation, a pre-check that replaces the reviewer, an unmarked AI draft circulating on the shop floor each one recreates the failure FDA cited in its first AI-specific warning letter. Keep the boundary physical: outputs marked as drafts or working aids, and every record created only by human review and signature.
About the author
Kinjal Patel
Kinjal has spent 10 years in pharmaceutical quality assurance across QMS, validation, qualification, vendor management, quality risk management, documentation, and in-process quality control, on oral solid and injectable manufacturing including batch document preparation and issuance, batch record review, IPQA, product quality review, and training management
